Target-based molecular modeling strategies for schistosomiasis drug discovery

Future Medicinal Chemistry

Volumn 7, Issue 6, 2015, Pages 753-764

  Ferreira, Leonardo G ^a   Oliva, Glaucius ^a   Andricopulo, Adriano D ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

3 OXOACYL ACYL CARRIER PROTEIN REDUCTASE; ALBENDAZOLE; ANTISCHISTOSOMAL AGENT; ATORVASTATIN; CALCIUM CHANNEL; COLCHICINE; DOCETAXEL; ENZYME INHIBITOR; FLUINDOSTATIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE 8; IMATINIB; MEBENDAZOLE; MEVINOLIN; NEW DRUG; PACLITAXEL; PRAZIQUANTEL; PROTEIN TYROSINE KINASE; PURINE NUCLEOSIDE DERIVATIVE; PURINE NUCLEOSIDE PHOSPHORYLASE; PURINE NUCLEOSIDE PHOSPHORYLASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN; TIABENDAZOLE; VINBLASTINE; VINCRISTINE; ANTHELMINTIC AGENT;

BINDING AFFINITY; BINDING SITE; BIOINFORMATICS; BIOLOGICAL ACTIVITY; CHEMOTHERAPY; CONFORMATIONAL TRANSITION; DRUG REPOSITIONING; ENZYME ACTIVITY; FUNCTIONAL GENOMICS; GENE FUNCTION; GENE INTERACTION; HISTONE ACETYLATION; HISTONE METHYLATION; HISTONE PHOSPHORYLATION; HISTONE UBIQUITINATION; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR MECHANICS; MOLECULAR MODEL; MOLECULAR RECOGNITION; MUSCLE CONTRACTION; NEGLECTED TROPICAL DISEASE; NONHUMAN; PARALYSIS; PHARMACOPHORE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; QUANTUM MECHANICS; REVIEW; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; TROPICAL DISEASE; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; NEGLECTED DISEASES; PARASITOLOGY; PROCEDURES; SCHISTOSOMA;

ANIMALS; ANTHELMINTICS; COMPUTER SIMULATION; DRUG DISCOVERY; HUMANS; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; NEGLECTED DISEASES; SCHISTOSOMA; SCHISTOSOMIASIS;

EID: 84929752832     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.21     Document Type: Review

References (73)

1. World Health Organization. First WHO report on neglected tropical diseases: working to overcome the global impact of neglected tropical diseases. http://whqlibdoc.who.int
2. Fenwick A. The global burden of neglected tropical diseases. Public Health 126(3), 233-236 (2012).
3. Hotez PJ, Dumonteil E, Cravioto MB et al. An unfolding tragedy of Chagas disease in North America. PLoS Negl. Trop. Dis. 7(10), e2300 (2013).
4. Nwaka S, Hudson A. Innovative lead discovery strategies for tropical diseases. Nat. Rev. Drug Discov. 5(11), 941-955 (2006).
5. Jakobsen PH, Wang M, Nwaka S. Innovative partnerships for drug discovery against neglected diseases. PLoS Negl. Trop. Dis. 5(9), e1221 (2011).
6. Linehan M, Hanson C, Weaver A et al. Integrated implementation of programs targeting neglected tropical diseases through preventive chemotherapy: proving the feasibility at national scale. Am. J. Trop. Med. Hyg. 84(1), 5-14 (2011).
7. Bush S, Hopkins AD. Public-private partnerships in neglected tropical disease control: the role of nongovernmental organizations. Acta Trop. 120(Suppl. 1), S169-S172 (2011).
8. Colley DG, Bustinduy AL, Secor WE, King CH. Human schistosomiasis. Lancet 383 (9936), 2253-2264 (2014).
9. Gray DJ, Ross AG, Li YS, McManus DP. Diagnosis and management of schistosomiasis. BMJ 342, d2651 (2011).
10. World Health Organization. Sustaining the drive to overcome the global impact of neglected tropical diseases: second WHO report on neglected tropical diseases. www.who.int
11. Ezeamama AE, McGarvey ST, Hogan J et al. Treatment for Schistosoma japonicum reduction of intestinal parasite load, and cognitive test score improvements in school-aged children. PLoS Negl. Trop. Dis. 6(5), e1634 (2012).
12. Thétiot-Laurent SAL, Boissier J, Robert A, Meunier B. Schistosomiasis chemotherapy. Angew. Chem. Int. Ed. Engl. 52(31), 7936-7956 (2013).
13. Taman A, Azab M. Present-day anthelmintics and perspectives on future new targets. Parasitol. Res. 113(7), 2425-2433 (2014).
14. Caffrey CR, Secor WE. Schistosomiasis: from drug deployment to drug development. Curr. Opin. Infect. Dis. 24(5), 410-417 (2011).
15. Pammolli F, Magazzini L, Riccaboni M. The productivity crisis in pharmaceutical R&D. Nat. Rev. Drug Discov. 10(6), 428-438 (2011).
16. Juliano RL. Pharmaceutical innovation and public policy: the case for a new strategy for drug discovery and development. Sci. Publ. Policy 40(3), 393-405 (2013).
17. Ferreira LG, Andricopulo AD. Medicinal chemistry approaches to neglected diseases drug discovery. J. Mod. Med. Chem. 2(1), 20-31 (2014).
18. Taboureau O, Baell JB, Fernández-Recio J, Villoutreix BO. Established and emerging trends in computational drug discovery in the structural genomics era. Chem. Biol. 19(1), 29-41 (2012).
19. Weigelt J. Structural genomics - impact on biomedicine and drug discovery. Exp. Cell Res. 316(8), 1332-1338 (2010).
20. Takeda JI, Suzuki Y, Sakate R et al. H-DBAS: humantranscriptome database for alternative splicing: update 2010. Nucleic Acids Res. 38(Suppl. 1), D86-D90 (2010).
21. Kumar S, Jena L, Daf S, Mohod K, Goyal P, Varma AK. hpvPDB: an online proteome reserve for human papillomavirus. Genomics Inform. 11(4), 289-291 (2013).
22. Wishart DS, Jewison T, Guo AC et al. HMDB 3.0 - the human metabolome database in 2013. Nucleic Acids Res. 41, D801-D807 (2013).
23. Gaulton A, Bellis LJ, Bento AP et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 40(D1), D1100-D1107 (2012).
24. Benson DA, Cavanaugh M, Clark K et al. GenBank. Nucleic Acids Res. 41, D36-D42 (2013).
25. Wilson GL, Lill MA. Integrating structure-based and ligand-based approaches for computational drug design. Future Med. Chem. 3(6), 735-750 (2011).
26. Blaney J. A very short history of structure-based design: how did we get here and where do we need to go? J. Comput. Aided Mol. Des. 26(1), 13-14 (2012).
27. Lionta E, Spyrou G, Vassilatis DK, Cournia Z. Structure-based virtual screening for drug discovery: principles, applications and recent advances. Curr. Top. Med. Chem. 14(16), 1923-1938 (2014).
28. Vidler LR, Filippakopoulos P, Fedorov O et al. Discovery of novel small-molecule inhibitors of BRD4 using structure-based virtual screening. J. Med. Chem. 56(20), 8073-8088 (2013).
29. Valasani KR, Vangavaragu JR, Day VW, Yan SS. Structure based design, synthesis, pharmacophore modeling, virtual screening, and molecular docking studies for identification of novel cyclophilin D inhibitors. J. Chem. Inf. Model. 54(3), 902-912 (2014).
30. Berman HM, Westbrook J, Feng Z et al. The protein data bank. Nucleic Acids Res. 28(1), 235-242 (2000).
31. Leach AR, Gillet VJ, Lewis RA, Taylor R. Threedimensional pharmacophore methods in drug discovery. J. Med. Chem. 53(2), 539-558 (2010).
32. Mittal A, Paliwal S, Sharma M, Singh A, Sharma S, Yadav D. Pharmacophore based virtual screening, molecular docking and biological evaluation to identify novel PDE5 inhibitors with vasodilatory activity. Bioorg. Med. Chem. Lett. 24(14), 3137-3141 (2014).
33. Verma J, Khedkar VM, Coutinho EC. 3D-QSAR in drug design - a review. Curr. Top. Med. Chem. 10(1), 95-115 (2010).
34. Mavromoustakos T, Durdagi S, Koukoulitsa C et al. Strategies in the rational drug design. Curr. Med. Chem. 18(17), 2517-2530 (2011).
35. Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, Coleman RG. ZINC: a free tool to discover chemistry for biology. J. Chem. Inf. Model. 52(7), 1757-1768 (2012).
36. Wang Y, Xiao J, Suzek TO, Zhang J, Wang J, Bryant SH. PubChem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids Res. 37(Suppl. 2), W623-W633 (2009).
37. Caffrey CR. Chemotherapy of schistosomiasis: present and future. Curr. Opin. Chem. Biol. 11(4), 433-439 (2007).
38. Gilbert IH. Drug discovery for neglected diseases: molecular target-based and phenotypic approaches: miniperspectives series on phenotypic screening for antiinfective targets. J. Med. Chem. 56(20), 7719-7726 (2013).
39. Berriman M, Haas BJ, LoVerde PT et al. The genome of the blood fluke Schistosoma mansoni. Nature 460 (7253), 352-358 (2009).
40. Zhou Y, Zheng H, Chen Y et al. The Schistosoma japonicum genome reveals features of host-parasite interplay. Nature 460 (7253), 345-351 (2009).
41. Young ND, Jex AR, Li B et al. Whole-genome sequence of Schistosoma haematobium. Nat. Genet. 44(2), 221-225 (2012).
42. Caffrey CR, Rohwer A, Oellien F et al. A comparative chemogenomics strategy to predict potential drug targets in the metazoan pathogen, Schistosoma mansoni. PLoS ONE 4(2), e4413 (2009).
43. Zerlotini A, Heiges M, Wang H et al. SchistoDB: a Schistosoma mansoni genome resource. Nucleic Acids Res. 37(Suppl. 1), D579-D582 (2009).
44. Logan-Klumpler FJ, De Silva N, Boehme U et al. GeneDB - an annotation database for pathogens. Nucleic Acids Res. 40(D1), D98-D108 (2012).
45. De Sousa TN, De Menezes Neto A, De Brito CFA. "Omics" in the study of the major parasitic diseases malaria and schistosomiasis. Infect. Genet. Evol. 19, 258-273 (2013).
46. Rana AK, Misra-Bhattacharya S. Current drug targets for helminthic diseases. Parasitol. Res. 112(5), 1819-1831 (2013).
47. Njoroge M, Njuguna NM, Mutai P, Ongarora DS, Smith PW, Chibale K. Recent approaches to chemical discovery and development against malaria and the neglected tropical diseases human African trypanosomiasis and schistosomiasis. Chem. Rev. 114(22), 11138-11163 (2014).
48. Schiedel M, Marek M, Lancelot J et al. Fluorescence-based screening assays for the NAD +-dependent histone deacetylase smSirt2 from Schistosoma mansoni. J. Biomol. Screen. 20(1), 112-121 (2015).
49. Pitkänen E, Rousu J, Ukkonen E. Computational methods for metabolic reconstruction. Curr. Opin. Biotechnol. 21(1), 70-77 (2010).
50. Shinde S, Mol M, Singh S. Regulatory networks, genes and glycerophospholipid biosynthesis pathway in schistosomiasis: a systems biology view for pharmacological intervention. Gene 550(2), 214-222 (2014).
51. Rojo-Arreola L, Long T, Asarnow D, Suzuki BM, Singh R, Caffrey CR. Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis. PLoS ONE 9(1), e87594 (2014).
52. Buro C, Beckmann S, Oliveira KC et al. Imatinib treatment causes substantial transcriptional changes in adult Schistosoma mansoni in vitro exhibiting pleiotropic effects PLoS Negl. Trop. Dis. 8(6), e2923 (2014).
53. Greuber EK, Smith-Pearson P, Wang J, Pendergast AM. Role of ABL family kinases in cancer: from leukaemia to solid tumours. Nat. Rev. Cancer 13(8), 559-571 (2013).
54. Hantschel O, Grebien F, Superti-Furga G. The growing arsenal of ATP-competitive and allosteric inhibitors of BCR- ABL. Cancer Res. 72(19), 4890-4895 (2012).
55. Beckmann S, Quack T, Burmeister C et al. Schistosoma mansoni: signal transduction processes during the development of the reproductive organs. Parasitology 137(3), 497-520 (2010).
56. Beckmann S, Hahnel S, Cailliau K et al. Characterization of the Src/Abl hybrid kinase SmTK6 of Schistosoma mansoni. J. Biol. Chem. 286(49), 42325-42336 (2011).
57. Nagar B, Bornmann WG, Pellicena P et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 62(15), 4236-43 (2002).
58. Pereira HM, Cleasby A, Pena SED, Franco GOR, Garratt RC. Cloning, expression and preliminary crystallographic studies of the potential drug target purine nucleoside phosphorylase from Schistosoma mansoni. Acta Crystallogr. D Biol. Crystallogr. 59(6), 1096-1099 (2003).
59. Postigo MP, Krogh R, Terni MF et al. Enzyme kinetics, structural analysis and molecular modeling studies on a series of Schistosoma mansoni PNP inhibitors. J. Braz. Chem. Soc. 22(3), 583-591 (2011).
60. Castilho MS, Postigo MP, Pereira HM, Oliva G, Andricopulo AD. Structural basis for selective inhibition of purine nucleoside phosphorylase from Schistosoma mansoni: Kinetic and structural studies. Bioorg. Med. Chem. 18(4), 1421-1427 (2010).
61. Postigo MP, Guido RV, Oliva G et al. Discovery of new inhibitors of Schistosoma mansoni PNP by pharmacophorebased virtual screening. J. Chem. Inf. Model. 50(9), 1693-1705 (2010).
62. Payne DJ, Warren PV, Holmes DJ, Ji Y, Lonsdale JT. Bacterial fatty-acid biosynthesis: a genomics-driven target for antibacterial drug discovery. Drug Discov. Today 6(10), 537-544 (2001).
63. Liu J, Dyer D, Wang J et al. 3-oxoacyl-ACP reductase from Schistosoma japonicum: integrated in silico-in vitro strategy for discovering antischistosomal lead compounds. PloS ONE 8(6), e64984 (2013).
64. Brouwers JF, Versluis C, van Golde LM, Tielens AG. 5-Octadecenoic acid: evidence for a novel type of fatty acid modification in schistosomes. Biochem. J. 334(Pt 2), 315-319 (1998).
65. Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 21(3), 381-395 (2011).
66. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell 150(1), 12-27 (2012).
67. Marek M, Kannan S, Hauser AT et al. Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni. PLoS Pathog. 9(9), e1003645 (2013).
68. Kannan S, Melesina J, Hauser AT et al. Discovery of inhibitors of Schistosoma mansoni HDAC8 by combining homology modeling, virtual screening, and in vitro validation. J. Chem. Inf. Model. 54(10), 3005-3019 (2014).
69. Singh J, Petter RC, Baillie TA, Whitty A. The resurgence of covalent drugs. Nat. Rev. Drug Discov. 10(4), 307-317 (2011).
70. Ouyang X, Zhou S, Su CTT, Ge Z, Li R, Kwoh CK. CovalentDock: automated covalent docking with parameterized covalent linkage energy estimation and molecular geometry constraints. J. Comput. Chem. 34(4), 326-336 (2013).
71. Xu M, Lill MA. Induced fit docking, and the use of QM/MM methods in docking. Drug Discov. Today Technol. 10(3), e411-e418 (2013).
72. Menikarachchi LC, Gascón JA. QM/MM approaches in medicinal chemistry research. Curr. Top. Med. Chem. 10(1), 46-54 (2010).
73. Fanfrlik J, Brahmkshatriya PS, Řezáč J et al. Quantum mechanics-based scoring rationalizes the irreversible inactivation of parasitic Schistosoma mansoni cysteine peptidase by vinyl sulfone inhibitors. J. Phys. Chem. B. 117(48), 14973-14982 (2013).